Preferred Label : Imdevimab;

NCIt definition : A recombinant, human immunoglobulin G1 (IgG1) lambda monoclonal antibody directed against the spike protein (SP) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for immunization against COVID-19. Upon administration, imdevimab specifically targets and binds to the receptor-binding domain (RBD) of SP, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2.;

UNII : 2Z3DQD2JHM;

CAS number : 2415933-40-1; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2415933-40-1 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Molecule name : REGN 10987; REGN-10987;

NCI Metathesaurus CUI : CL1642857;

Details


Main resources

You can consult :


https://ansm.sante.fr/tableau-atu-rtu/casirivimab-imdevimab-120-mg-ml-solution-a-diluer-pour-perfusion-intraveineuse-ou-solution-pour-injection-sous-cutanee
2021
false
false
false
France
French
guidelines for drug use
antibodies, monoclonal, humanized
Casirivimab/Imdevimab
Casirivimab
infusions, intravenous
drug combinations
Imdevimab
summary of product characteristics
package leaflet
adult
aged
COVID-19
imdevimab
casirivimab and imdevimab drug combination
casirivimab
casirivimab and imdevimab drug combination
casirivimab and imdevimab
Pre-Exposure Prophylaxis
Product containing only casirivimab and imdevimab in parenteral dose form (medicinal product form)
Post-Exposure prophylaxis
casirivimab and imdevimab drug combination

---
https://www.ansm.sante.fr/actualites/anticorps-monoclonaux-lansm-permet-lutilisation-en-acces-precoce-de-deux-bitherapies-contre-la-covid-19
2021
false
false
false
France
French
scientific and technical information
drug information
antibodies, monoclonal
adult
Casirivimab/Imdevimab
Casirivimab
Imdevimab
Anti-spike Protein SARS-CoV-2 Monoclonal Antibody
Bamlanivimab
Etesevimab
aged
spike glycoprotein, coronavirus
france
drug monitoring
risk
drug combinations
casirivimab and imdevimab drug combination
COVID-19
COVID-19
casirivimab
imdevimab
casirivimab and imdevimab
drug combinations
antibodies, monoclonal, humanized
Product containing only casirivimab and imdevimab in parenteral dose form (medicinal product form)
casirivimab and imdevimab drug combination

---
Nous contacter.
21/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.